Palliative Medicine
January 22, 2024
Louis Plourde, Sue-Ling Chang, Houman Farzin et al.
22 citations
A survey of 2,800 adults in four Canadian provinces found high social acceptability of psilocybin-assisted therapy for existential distress at the end of life. 79.3% considered it a reasonable medical choice, 84.8% agreed public health insurance should cover it, and 63.3% would support legalization for medical purposes. More favorable attitudes were linked to prior psilocybin use, exposure to palliative care, and progressive political orientation. The findings suggest public support is strong enough to help mobilize resources and improve access to this emerging therapy in palliative and end-of-life care.
Palliative & supportive care
October 1, 2024
Marianne Masse-Grenier, Sue-Ling Chang, Ariane Bélanger et al.
4 citations
Palliative care professionals see psilocybin-assisted therapy as a promising treatment for existential distress in patients with serious illnesses, but they have several concerns. In a qualitative study using World Café methodology with 16 palliative care professionals, participants identified needs for educational and certified training, medical legalization of psilocybin, more research, refined therapy protocols, and clarity on who dispenses the therapy, where it is given, and eligibility criteria. The acceptability of the therapy and expanding access appear interrelated, and developing guidelines will be essential for wider deployment.
Palliative Medicine
May 19, 2026
Louis Plourde, Sue-Ling Chang, Olivia Nguyen et al.
1 citation
Most palliative care stakeholders in Canada view psilocybin-assisted therapy favorably, with 95% of physicians reporting positive attitudes. A cross-sectional online survey of 121 adults involved in palliative care found that the lack of trained healthcare providers is the primary barrier to implementation, while further research and standardized protocols are key facilitators. Sixty-eight percent of stakeholders support introducing this therapy early in the illness trajectory. The findings highlight significant divergence in perspectives between clinical and non-clinical groups, suggesting tailored interprofessional education could build shared understanding. The study's Canadian context may limit transferability to other regulatory frameworks.
Journal of Psychedelic Studies
January 21, 2025
Louis Plourde, Sue-Ling Chang, Houman Farzin et al.
1 citation
The debate about whether psychotherapists should personally experience non-ordinary states of consciousness during psilocybin-assisted therapy training is important because it influences treatment safety, effectiveness, and accessibility. Ethical and practical concerns about making such experience a training standard need urgent attention where psilocybin therapy is being integrated into healthcare. The authors argue that the most balanced and ethical approach is to legally allow psilocybin use for professional training but not require it.